Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results
Yıl: 2020 Cilt: 29 Sayı: 4 Sayfa Aralığı: 313 - 317 Metin Dili: İngilizce DOI: 10.37845/ret.vit.2020.29.57 İndeks Tarihi: 29-05-2021
Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results
Öz: Purpose: To investigate the two-year visual and anatomical outcomes of patients who had intravitreal afl ibercept monotherapy for macular edema due to branch retinal vein occlusion (BRVO). Methods: Twenty-nine eyes were included in this retrospective cohort study. All eyes were newly diagnosed as BRVO and were treated with intravitreal injections of afl ibercept. After three-months loading doses, patients were treated with a single dose of afl ibercepts if needed. The best-corrected visual acuity (BCVA) and the central macular thickness (CMT) were recorded at each monthly visit. Results: The mean ages of patients were 61.3±7.6 years. The mean BCVA was 52.2±8.5 letters at baseline, 70.1±11.2 letters at the fi rst year (p<0.001), 69.7±12.5 letters at the second year (p<0.001). The mean CMT was 555±102 μm at baseline; 285±50 μm at the fi rst year (p<0.001), 270±52 μm at the second year (p<0.001). In the fi rst year, the mean number of injections was 5.9±1.2 whereas in the second year it was 2.1±0.9.Conclusion: These long-term real-life results suggest that the intravitreal afl ibercept is an effective treatment regimen for eyes with macular edema in BRVO.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
- 1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313-9.e1. doi:10.1016/j. ophtha.2009.07.017
- 2. Lashay A, Riazi-Esfahani H, Mirghorbani M, et al. Intravitreal Medications for Retinal Vein Occlusion: Systematic Review and Meta-analysis. J Ophthalmic Vis Res. 2019;14:336-66. doi:10.18502/jovr.v14i3.4791
- 3. Babiuch AS, Han M, Conti FF, et al. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion. JAMA Ophthalmol. 2019;137:38-46. doi:10.1001/ jamaophthalmol.2018.4484
- 4. Ho M, Liu DTL, Lam DSC, et al. Retinal Vein Occlusions, From Basics to The Latest Treatment. Retina. 2016;36:432- 48. doi:10.1097/IAE.0000000000000843
- 5. Kaya F, Kocak I, Aydin A, et al. Comparison of Intravitreal Afl ibercept and Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion. J RetVit. 2018;27:1-10.
- 6. Hoy SM. Afl ibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion. Drugs Aging. 2017;34:393-400. doi:10.1007/s40266-017-0458-6.
- 7. Heier JS, Clark WL, Boyer DS, et al. Intravitreal afl ibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121:1414-1420.e1. doi:10.1016/j. ophtha.2014.01.027
- 8. Brown DM, Heier JS, Clark WL, et al. Intravitreal afl ibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155:429-37.e7. doi:10.1016/j. ajo.2012.09.026
- 9. Spooner K, Hong T, Fraser-Bell S, et al. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis. Ophthalmol J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkd. 2019;242:163-77. doi:10.1159/000497492
- 10. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97:278-84. doi:10.1136/bjophthalmol-2012-301504
- 11. Sırakaya E, Küçük B, Ağadayı A. Afl ibercept Treatment for Macular Edema following Branch Retinal Vein Occlusion: Age-Based Responses. Ophthalmologica. 2020;243:94-101. doi:10.1159/000502042
- 12. Clark WL, Boyer DS, Heier JS, et al. Intravitreal Afl ibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016;123:330-6. doi:10.1016/j.ophtha.2015.09.035
- 13. Pichi F, Elbarky AM, Elhamaky TR. Outcome of “treat and monitor” regimen of afl ibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Int Ophthalmol. 2019;39:145-53. doi:10.1007/ s10792-017-0798-6
| APA | SIRAKAYA E, KILIC D (2020). Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. , 313 - 317. 10.37845/ret.vit.2020.29.57 |
| Chicago | SIRAKAYA ENDER,KILIC Deniz Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. (2020): 313 - 317. 10.37845/ret.vit.2020.29.57 |
| MLA | SIRAKAYA ENDER,KILIC Deniz Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. , 2020, ss.313 - 317. 10.37845/ret.vit.2020.29.57 |
| AMA | SIRAKAYA E,KILIC D Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. . 2020; 313 - 317. 10.37845/ret.vit.2020.29.57 |
| Vancouver | SIRAKAYA E,KILIC D Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. . 2020; 313 - 317. 10.37845/ret.vit.2020.29.57 |
| IEEE | SIRAKAYA E,KILIC D "Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results." , ss.313 - 317, 2020. 10.37845/ret.vit.2020.29.57 |
| ISNAD | SIRAKAYA, ENDER - KILIC, Deniz. "Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results". (2020), 313-317. https://doi.org/10.37845/ret.vit.2020.29.57 |
| APA | SIRAKAYA E, KILIC D (2020). Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. Retina-Vitreus, 29(4), 313 - 317. 10.37845/ret.vit.2020.29.57 |
| Chicago | SIRAKAYA ENDER,KILIC Deniz Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. Retina-Vitreus 29, no.4 (2020): 313 - 317. 10.37845/ret.vit.2020.29.57 |
| MLA | SIRAKAYA ENDER,KILIC Deniz Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. Retina-Vitreus, vol.29, no.4, 2020, ss.313 - 317. 10.37845/ret.vit.2020.29.57 |
| AMA | SIRAKAYA E,KILIC D Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. Retina-Vitreus. 2020; 29(4): 313 - 317. 10.37845/ret.vit.2020.29.57 |
| Vancouver | SIRAKAYA E,KILIC D Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results. Retina-Vitreus. 2020; 29(4): 313 - 317. 10.37845/ret.vit.2020.29.57 |
| IEEE | SIRAKAYA E,KILIC D "Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results." Retina-Vitreus, 29, ss.313 - 317, 2020. 10.37845/ret.vit.2020.29.57 |
| ISNAD | SIRAKAYA, ENDER - KILIC, Deniz. "Afl ibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-Year Results". Retina-Vitreus 29/4 (2020), 313-317. https://doi.org/10.37845/ret.vit.2020.29.57 |
